Guido Neels Buys 20,000 Shares of Elutia (NASDAQ:ELUT) Stock

Elutia Inc. (NASDAQ:ELUT) Director Guido Neels purchased 20,000 shares of Elutia stock in a transaction that occurred on Friday, January 30th. The shares were bought at an average price of $1.04 per share, for a total transaction of $20,800.00. Following the transaction, the director directly owned 118,750 shares of the company’s stock, valued at $123,500. This trade represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Elutia Price Performance

Shares of ELUT opened at $0.98 on Wednesday. The company has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.15. The firm has a market capitalization of $41.85 million, a PE ratio of -1.07 and a beta of 0.67. Elutia Inc. has a one year low of $0.50 and a one year high of $3.46.

Elutia (NASDAQ:ELUT) last announced its earnings results on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.15. The firm had revenue of $3.32 million during the quarter, compared to the consensus estimate of $6.65 million. Analysts expect that Elutia Inc. will post -1.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on ELUT. Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Elutia to a “sell” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $7.00.

Institutional Trading of Elutia

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new position in Elutia in the fourth quarter worth about $25,000. Citadel Advisors LLC bought a new stake in shares of Elutia during the third quarter valued at approximately $50,000. Virtu Financial LLC bought a new stake in shares of Elutia during the third quarter valued at approximately $26,000. Deerfield Management Company L.P. purchased a new position in Elutia in the 3rd quarter worth approximately $1,221,000. Finally, XTX Topco Ltd bought a new position in Elutia in the 2nd quarter valued at approximately $28,000. 74.03% of the stock is currently owned by institutional investors.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.